ACT 709478

Drug Profile

ACT 709478

Alternative Names: ACT709478

Latest Information Update: 30 May 2017

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Antiepileptic drugs; Immunotherapies
  • Mechanism of Action T-type calcium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epilepsy

Most Recent Events

  • 29 May 2017 Phase-I clinical trials in Epilepsy before May 2017 (PO)
  • 29 May 2017 Actelion plans a phase I trial in Healthy volunteers in Germany (NCT03165097)
  • 29 May 2017 Actelion plans a phase II trial for Epilepsy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top